Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Chromatogr B Analyt Technol Biomed Life Sci ; 846(1-2): 162-8, 2007 Feb 01.
Article in English | MEDLINE | ID: mdl-17005456

ABSTRACT

A rapid and sensitive liquid chromatography-tandem mass spectrometric method (LC-MS/MS) had been developed and validated to determine the concentrations of BPR0L075 in rat plasma. After a simple protein precipitation of plasma samples by acetonitrile, BPR0L075 was analyzed on a C(8) column at a flow rate of 0.5 mL/min. The mobile phase consisted of a mixture of 10 mM ammonium acetate containing 0.1% formic acid and acetonitrile (20:80, v/v). Both BPR0L075 (analyte) and the internal standard (BPR0L092) were determined using electro-spray ionization and the MS data acquisition was via multiple reactions monitoring (MRM) in positive scanning model. The MS/MS ion transitions monitored are m/z 342.2/195.2 and 312.5/165.2 for BPR0L075 and BPR0L092, respectively. The low limit of quantitation was 0.5 ng/mL. Each plasma sample was chromatographed within 5 min. The method was validated with respect to linearity, accuracy, precision, recovery, and stability. A good linear relationship was observed over the concentration range of 0.5-1000 ng/mL (r>0.9994). Absolute recoveries ranged from 63.45 to 68.34% in plasma at the concentrations of 2, 40, 400, and 800 ng/mL. The intra- and inter-day accuracy ranged from 92.04 to 111.80%. Intra- and inter-day relative standard deviations were 1.08-3.29% and 1.96-5.46%, respectively. This developed and validated assay method had been successfully applied to a pharmacokinetic study after intravenous injection of BPR0L075 in rats at a dose of 5mg/kg.


Subject(s)
Chromatography, Liquid/methods , Indoles/blood , Mitosis/drug effects , Tandem Mass Spectrometry/methods , Animals , Indoles/pharmacokinetics , Indoles/pharmacology , Rats , Reproducibility of Results , Sensitivity and Specificity
2.
ChemMedChem ; 1(10): 1106-18, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16952120

ABSTRACT

The concise synthesis and structure-activity relationship (SAR) studies of 3-aroylindoles were carried out in an effort to improve the potency and solubility of anticancer drug candidate BPR0L075 (8) by exploring structure modifications through three regimens: substitution of the B ring, at the N1 position, and of the 3-carbonyl linker. The SAR information revealed that the methoxy group of the B ring could be replaced with an electron-donating group such as methyl (in compound 9) or N,N-dimethylamino (in compound 13) while retaining both strong cytotoxic and antitubulin activities. The introduction of amide (compounds 30-33) and carbamate (compounds 34-37) functionalities at the N1 position of 8 gave analogues with potent antiproliferative activities. The cytotoxic potency of 8 was improved by replacing the carbonyl group with sulfide (compound 41) or oxygen (compound 43), indicating that the carbonyl moiety is important but not essential. The N,N-dimethylamino derivative 13 not only displayed potent cytotoxicity and antitubulin activity, but also showed a markedly improved physicochemical profile relative to the parent compound.


Subject(s)
Antimitotic Agents/pharmacology , Antineoplastic Agents/pharmacology , Indoles/pharmacology , Tubulin Modulators/pharmacology , Animals , Antimitotic Agents/chemical synthesis , Antimitotic Agents/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , Humans , In Vitro Techniques , Indoles/chemical synthesis , Indoles/chemistry , Male , Molecular Structure , Rats , Rats, Sprague-Dawley , Stereoisomerism , Structure-Activity Relationship , Tubulin/drug effects , Tubulin Modulators/chemical synthesis , Tubulin Modulators/chemistry , Tumor Cells, Cultured
3.
J Med Chem ; 49(1): 373-80, 2006 Jan 12.
Article in English | MEDLINE | ID: mdl-16392822

ABSTRACT

Dipeptidyl peptidase IV (DPP-IV) inhibitors are expected to become a new type of antidiabetic drugs. Most known DPP-IV inhibitors often resemble the dipeptide cleavage products, with a proline mimic at the P1 site. As off-target inhibitions of DPP8 and/or DPP9 have shown profound toxicities in the in vivo studies, it is important to develop selective DPP-IV inhibitors for clinical usage. To achieve this, a new class of 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-based DPP-IV inhibitors was synthesized. SAR studies resulted in a number of DPP-IV inhibitors, having IC(50) values of <50 nM with excellent selectivity over both DPP8 (IC(50) > 100 microM) and DPP-II (IC(50) > 30 microM). Compound 21a suppressed the blood glucose elevation after an oral glucose challenge in Wistar rats and also inhibited plasma DPP-IV activity for up to 4 h in BALB/c mice. The results show that compound 21a possesses in vitro and in vivo activities comparable to those of NVP-LAF237 (4), which is in clinical development.


Subject(s)
Dipeptidyl Peptidase 4/drug effects , Enzyme Inhibitors/pharmacology , Isoquinolines/pharmacology , Pyrrolidinones/pharmacology , Administration, Oral , Animals , Blood Glucose/drug effects , Dipeptidases/antagonists & inhibitors , Dipeptidyl Peptidase 4/blood , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors , Drug Evaluation, Preclinical , Drug Tolerance , Enzyme Inhibitors/chemical synthesis , Glucose/administration & dosage , Glucose/antagonists & inhibitors , Humans , In Vitro Techniques , Isoquinolines/chemical synthesis , Male , Mice , Mice, Inbred BALB C , Molecular Conformation , Pyrrolidinones/chemical synthesis , Rats , Rats, Wistar , Structure-Activity Relationship , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...